Prior Presenting Companies
Tuesday, JUNE 16 10:00AM ET
Leveraging proprietary neurodegenerative disease platform and growing body of compelling data to advance the first potential approved treatment for Huntington’s disease
NASDAQ: VCNX
Maurice Zauderer, Ph.D.
President and Chief Executive Officer
Vaccinex, Inc. (Nasdaq: VCNX) is a publicly traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.
Tuesday, JUNE 16 12:00pM ET
A Targeted Approach to CAR T Cell Therapy
NASDAQ: XBIO
Jeffrey F. Eisenberg
Chief Executive Officer
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Tuesday, JUNE 16 2:00pM ET
NYSE American: NAVB
NYSE American: NAVB
Jed A. Latkin
Chief Executive Officer, Chief Financial Officer
and Chief Operating Officer
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
© 2020 Virtual Investor All rights reserved.
